SCHEMBL10043901

SCHEMBL10043901

Cc1ccc(NC(=O)c2ccc(C)c(-c3cc4cnc(C)cc4n(C)c3=O)c2)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 3/20 0.49
KCNQ2 O43526 3/20 0.49
SYK P43405 1/20 0.47
MAPK14 Q16539 9/20 0.45
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
KCNE1 P15382 1/20 0.42
KCNQ1 P51787 1/20 0.42
MAPKAPK2 P49137 2/20 0.41
LCK P06239 1/20 0.41
KIT P10721 1/20 0.41
KDR P35968 1/20 0.41
NAMPT P43490 1/20 0.41
ABL1 P00519 1/20 0.41
P4HTM Q9NXG6 1/20 0.41
CYP2C9 P11712 1/20 0.40
BRAF P15056 1/20 0.40
MAPK13 O15264 1/20 0.40
RAF1 P04049 1/20 0.40
PDGFRA P16234 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043922 0.92 MAPK14 (0.48) KCNQ3KCNQ2SYKMAPK14MAPT
SCHEMBL10043675 0.92 SYK (0.49) KCNQ3KCNQ2SYKMAPK14POLB
SCHEMBL13438140 0.92 SMN1; SMN2 (0.46) KCNQ3KCNQ2SYKMAPK14POLB
SCHEMBL10043891 0.91 SYK (0.43) KCNQ3KCNQ2SYKMAPK14POLB
SCHEMBL10043663 0.90 SYK (0.51) KCNQ3KCNQ2SYKMAPK14POLB
SCHEMBL10043705 0.89 MAPT (0.54) SYKMAPK14POLBMAPTABL1
SCHEMBL10043923 0.89 MAOB (0.53) KCNQ3KCNQ2SYKMAPK14POLB
SCHEMBL10043898 0.88 MAPK14 (0.47) KCNQ3KCNQ2SYKMAPK14KCNE1
SCHEMBL10043890 0.88 SYK (0.44) SYKMAPK14POLBMAPTMAPKAPK2
SCHEMBL10043924 0.87 MAPK14 (0.46) KCNQ3KCNQ2SYKMAPK14KCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC KCNQ3 2453/4885KCNQ2 2398/4885SYK 42/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC KCNQ3 2453/4885KCNQ2 2398/4885SYK 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.